AAL68977.1
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
46,426 Da
NCBI Official Full Name
Smad7
NCBI Official Synonym Full Names
SMAD family member 7
NCBI Protein Information
mothers against decapentaplegic homolog 7; hSMAD7; MAD homolog 8; mothers against DPP homolog 8; SMAD, mothers against DPP homolog 7; Mothers against decapentaplegic, drosophila, homolog of, 7; MAD (mothers against decapentaplegic, Drosophila) homolog 7
UniProt Protein Name
Mothers against decapentaplegic homolog 7
UniProt Synonym Protein Names
Mothers against decapentaplegic homolog 8; MAD homolog 8; Mothers against DPP homolog 8; SMAD family member 7
UniProt Synonym Gene Names
MADH7; MADH8; MAD homolog 7; Mothers against DPP homolog 7; MAD homolog 8; Mothers against DPP homolog 8; SMAD 7; Smad7; hSMAD7 [Similar Products]
UniProt Entry Name
SMAD7_HUMAN
NCBI Summary for SMAD7
The protein encoded by this gene is a nuclear protein that binds the E3 ubiquitin ligase SMURF2. Upon binding, this complex translocates to the cytoplasm, where it interacts with TGF-beta receptor type-1 (TGFBR1), leading to the degradation of both the encoded protein and TGFBR1. Expression of this gene is induced by TGFBR1. Variations in this gene are a cause of susceptibility to colorectal cancer type 3 (CRCS3). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2010]
UniProt Comments for SMAD7
SMAD7: Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A- PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Genetic variations in SMAD7 influence susceptibility to colorectal cancer type 3 (CRCS3). Colorectal cancer consists of tumors or cancer of either the colon or rectum or both. Cancers of the large intestine are the second most common form of cancer found in males and females. Symptoms include rectal bleeding, occult blood in stools, bowel obstruction and weight loss. Treatment is based largely on the extent of cancer penetration into the intestinal wall. Surgical cures are possible if the malignancy is confined to the intestine. Risk can be reduced when following a diet which is low in fat and high in fiber. Belongs to the dwarfin/SMAD family.
Protein type: DNA-binding; Transcription factor
Chromosomal Location of Human Ortholog: 18q21.1
Cellular Component: nucleoplasm; transcription factor complex; protein complex; cell-cell adherens junction; cytoplasm; plasma membrane; catenin complex; nucleus; cytosol
Molecular Function: collagen binding; protein binding; metal ion binding; ubiquitin protein ligase binding; activin binding; beta-catenin binding; transforming growth factor beta receptor, inhibitory cytoplasmic mediator activity; transcription factor activity
Biological Process: transcription initiation from RNA polymerase II promoter; transcription, DNA-dependent; protein stabilization; negative regulation of transcription factor activity; negative regulation of peptidyl-serine phosphorylation; negative regulation of transcription from RNA polymerase II promoter; regulation of activin receptor signaling pathway; negative regulation of BMP signaling pathway; BMP signaling pathway; regulation of transforming growth factor beta receptor signaling pathway; ureteric bud development; positive regulation of protein ubiquitination; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; transforming growth factor beta receptor signaling pathway; negative regulation of ubiquitin-protein ligase activity; positive regulation of cell-cell adhesion; artery morphogenesis; ventricular cardiac muscle morphogenesis; negative regulation of protein ubiquitination; positive regulation of transcription from RNA polymerase II promoter; gene expression; negative regulation of transforming growth factor beta receptor signaling pathway; negative regulation of cell migration
Disease: Colorectal Cancer, Susceptibility To, 3
Research Articles on SMAD7
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with SMAD7 elisa kit
Pathways associated with SMAD7 elisa kit
Diseases associated with SMAD7 elisa kit
Organs/Tissues associated with SMAD7 elisa kit
|